Literature DB >> 19236541

Assessment of fibrosis in chronic liver diseases.

Kun Zhou1, Lun Gen Lu.   

Abstract

The assessment of liver fibrosis provides useful information not only for diagnosis but also for therapeutic decisions. Although liver biopsy is the current gold standard for fibrosis assessment, it has some risks and limitations, including intra-observer and inter-observer variation, sampling error and variability. In recent years, many studies and great interest have been dedicated to the development of non-invasive tests to substitute a liver biopsy for fibrosis assessment and follow up. Advances in serological and radiological tests such as serum marker panels, transient elastography and their combinations can assess fibrosis accurately and reduce the need for a liver biopsy. But at present, all have failed to completely replace a liver biopsy because of their respective limitations and an imperfect gold standard used in current researches. The searching for an ideal surrogate is still in progress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236541     DOI: 10.1111/j.1751-2980.2008.00356.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  16 in total

1.  Normal values of liver elasticity measured by real-time tissue elastography (RTE) in healthy infants and children.

Authors:  Buket Selmi; Guido Engelmann; Ulrike Teufel; Saroa El Sakka; Monika Dadrich; Jens-Peter Schenk
Journal:  J Med Ultrason (2001)       Date:  2013-06-11       Impact factor: 1.314

2.  Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease.

Authors:  Meng Yin; Jayant A Talwalkar; Kevin J Glaser; Sudhakar K Venkatesh; Jun Chen; Armando Manduca; Richard L Ehman
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

Review 3.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

4.  Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.

Authors:  Jun Chen; Jayant A Talwalkar; Meng Yin; Kevin J Glaser; Schuyler O Sanderson; Richard L Ehman
Journal:  Radiology       Date:  2011-04-01       Impact factor: 11.105

5.  A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.

Authors:  Hiroki Tahara; Hitoshi Takagi; Ken Sato; Yasushi Shimada; Hiroki Tojima; Tomoyuki Hirokawa; Tatsuya Ohyama; Katsuhiko Horiuchi; Atsushi Naganuma; Hirotaka Arai; Satoru Kakizaki; Masatomo Mori
Journal:  J Gastroenterol       Date:  2011-05-19       Impact factor: 7.527

6.  MR T1ρ as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication.

Authors:  Feng Zhao; Yi-Xiang J Wang; Jing Yuan; Min Deng; Hing Lok Wong; Eagle S H Chu; Minnie Y Y Go; Gao-Jun Teng; Anil T Ahuja; Jun Yu
Journal:  Eur Radiol       Date:  2012-03-27       Impact factor: 5.315

7.  MR Elastography of Liver Disease: State of the Art.

Authors:  Jun Chen; Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Richard L Ehman
Journal:  Appl Radiol       Date:  2013-04

8.  Molecular MRI of liver fibrosis by a peptide-targeted contrast agent in an experimental mouse model.

Authors:  April M Chow; Mingqian Tan; Darwin S Gao; Shu Juan Fan; Jerry S Cheung; Kwan Man; Zheng-Rong Lu; Ed X Wu
Journal:  Invest Radiol       Date:  2013-01       Impact factor: 6.016

9.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

Review 10.  Non-invasive markers for hepatic fibrosis.

Authors:  Ancha Baranova; Priyanka Lal; Aybike Birerdinc; Zobair M Younossi
Journal:  BMC Gastroenterol       Date:  2011-08-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.